pharmaphorum
JANUARY 9, 2022
US medical device company Abbott has said it plans to launch a new range of ‘biowearable’ health devices aimed at consumers, in a move that builds on its expertise in glucose monitoring. The company’s chief executive – Robert Ford – made the announcement at the massive CES tech trade show in Las Vegas, a venue usually dedicated to new TVs, gaming equipment, new smartphones and the like.
Pharma Times
JANUARY 11, 2022
The partnership between Oxford University and SEEQC promises to accelerate the use of quantum computing within pharmaceutical research in order to reduce the development time required for drug production worldwide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
JANUARY 12, 2022
The company plans to launch a Phase Ib/II study of its compound NVG-291 in collaboration with researchers at Northwestern Universityâs Shirley Ryan AbilityLab.
NY Times
JANUARY 14, 2022
A federal judge found that Mr. Shkreli violated state and federal antitrust laws by trying to maintain a monopoly over a lifesaving drug and must pay back the excess profits.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JANUARY 11, 2022
With evidence growing that the current crop of COVID-19 vaccines are less protective against infection with Omicron, both Pfizer and Moderna have announced plans to develop new versions of their mRNA-based shots that are tailored to the new variant. Pfizer has said that a COVID-19 jab specifically targeting Omicron, as well as other existing variants, will begin human trials later this month and could be available as early as March.
Pharma Times
JANUARY 13, 2022
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Drug Channels
JANUARY 10, 2022
PCMA Business Forum. February 28 – March 1, 2022 JW Marriott Grande Lakes | Orlando, FL Register Today! www.pcma.com/businessforum. The PCMA Business Forum is PCMA's largest business networking and educational conference. PCMA’s PBM Members send a large number of executives from relevant business units including pharma and trade relations, specialty pharmacy, clinical and patient care services, and the c-suite.
pharmaphorum
JANUARY 14, 2022
The European Commission, EMA and national regulators within the EU have launched an initiative to change the way clinical trials are designed and run in order to position the bloc as an international “focal point” for clinical research. The broad strokes of the proposals are laid out in a document entitled Accelerating Clinical Trials in the EU (ACT EU) that lists priority actions that will be taken, including measures to allow greater use of innovative clinical trial designs.
Pharma Times
JANUARY 11, 2022
There is currently no cure for cystic fibrosis (CF), a debilitating, progressive condition with over 10,830 people in the UK currently diagnosed with the disease.
Outsourcing Pharma
JANUARY 13, 2022
With the amount of available data increasing and technology evolving, says a company leader, the job of data manager is more demanding than ever before.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
NY Times
JANUARY 11, 2022
A former Africa correspondent, who covered the height of the AIDS epidemic there 15 years ago, finds lessons in the remarkable progress against that virus for our current fight.
pharmaphorum
JANUARY 12, 2022
Roche has launched what it says is a first-of-its kind handheld glucose management device, backed up by a digital platform that aims to simplify the work of doctors and nurses as they deliver care to patients. The cobas pulse system is a point-of-care device that combines a glucose test strip reader with a touch screen that is used for displaying patient information and data, as well as analysing and sharing clinical results.
Pharma Times
JANUARY 12, 2022
Under current guidelines, individuals that test positive for COVID-19 may be able to leave self-isolation after 7 days if certain conditions are met.
Outsourcing Pharma
JANUARY 14, 2022
The World Health Organization has recommended the drugs for COVID-19 patients, broadening the range of therapies to combat the virus behind the pandemic.
Drug Channels
JANUARY 14, 2022
Today’s guest post comes from Jeremy Docken, Founder and Chief Strategy Officer at Kalderos. Jeremy describes Kalderos’ 340B rebate model. He discusses an independent research organization’s study of the 340B rebate model’s impact on covered entities’ cash flow. To learn more, download the whitepaper: The Kalderos 340B Rebate Model In Action: Ensuring a Thriving and Sustainable 340B Program.
pharmaphorum
JANUARY 14, 2022
Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing a digital health approach to the management of mental illness. Otsuka Medical Devices is also taking some rights to GrayMatters’ platform – called Prism – in Japan and some other Asian countries in connection with the financing, which was supported by Joy Ventures, J-Ventures, J-Impact, and existing backers Marius Nacht and Joyance Ventures.
Pharma Times
JANUARY 14, 2022
Vir Biotech has launched a new antibody research initiative, expanding its partnership with the Bill & Melinda Gates Foundation
Outsourcing Pharma
JANUARY 12, 2022
The pharma firm and collaborator Molecular Partners reported positive data out of their Phase II study for ensovibep, an antiviral for treating the virus.
Drug Channels
JANUARY 11, 2022
As I have highlighted in previous posts, retail pharmacies are experiencing a period of intense competition that continues to pressure prescription profits. What's more, the pharmacy shakeout is accelerating, as smaller competitors exit and larger companies reduce store count. . In the video below, I provide a brief overview of key challenges facing retail pharmacy this year.
pharmaphorum
JANUARY 13, 2022
In 2020, over half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders, overtaking the amount going to drug manufacturers for the first time, according to a new study. The report from Berkeley Research Group (BRG) – which was funded by the pharma industry trade group PhRMA – reveals a steady decrease in the proportion received by drugmakers from around 67% in 2013 to 49.5% in 2020.
Pharma Times
JANUARY 12, 2022
The test is hoped to provide patients with a more convenient means of access to treatment for respiratory issues.
NY Times
JANUARY 14, 2022
After one of his sons fell into a deep depression, he helped him recover. He later licensed an antidepressant that was a boon to his pharmaceutical company.
Eye on FDA
JANUARY 12, 2022
Each year we look back to take stock of how the agency has been communicating in the course of the previous year and assess how that might compare to years gone by. In fact from year to year, there is a good deal of change that occurs. When Dr. Scott Gottlieb took the reins of FDA as Commissioner, the amount of communications material put out jumped enormously.
pharmaphorum
JANUARY 12, 2022
The development of gene therapies for Duchenne muscular dystrophy has proved to be challenging, but one of the key players – Sarepta – thinks it may have the clinical data needed to file for regulator approval. The new data from the mid-stage Study 102 of SRP-9001 (delandistrogene moxeparvovec) comes from 21 patients who were initially in the placebo group of the study but crossed over to receive the gene therapy later.
Pharma Times
JANUARY 13, 2022
Despite diagnosis and treatment options improving for the rare kidney condition, further action is urgently required.
NY Times
JANUARY 11, 2022
If the preliminary decision is finalized this spring, it would sharply limit the number of patients who use the expensive drug.
Eye on FDA
JANUARY 9, 2022
Once again it was a quiet year with respect to the FDA’s Office of Prescription Drug Programs (OPDP). As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist.
pharmaphorum
JANUARY 11, 2022
As the COVID-19 pandemic continues to impact the healthcare landscape, and the digital transformation of the life sciences industry gathers pace, what can we expect to see in 2022? In this webinar, senior members from Healthware Group discuss the key trends and developments set to shape the industry and present their predictions for the year ahead. Join us on Friday 21 January at 2.00pm CET to find out how life science companies can stay ahead of the competition in 2022.
Pharma Times
JANUARY 10, 2022
The chronic, inflammatory disease affects an estimated 24 in every 10,000 people.
NY Times
JANUARY 11, 2022
The “vampire hormone” can act like a dose of sunset, tricking your body into feeling like it’s time to sleep.
Outsourcing Pharma
JANUARY 13, 2022
Performance Cell Manufacturing, a CDMO with a focus on manufacturing cell therapies, has been acquired by Great Point Partners and will now operate under the name Cellipont Bioservices.
pharmaphorum
JANUARY 12, 2022
Prospects for Aldeyra’s dry eye disease candidate reproxalap were hit last month after the drug failed to hit its primary objective in a phase 3 trial, but the company isn’t giving up and has new data showing an improvement over Novartis rival therapy Xiidra. Patients treated with reproxalap reported significantly less eye discomfort and itching than those using Xiidra (lifitegrast) in the new phase 2 trial, which Aldeyra said backs up early tolerability comparisons between the drugs
Pharma Times
JANUARY 10, 2022
Since April 2021, around 84,000 pregnant women have received at least one COVID-19 vaccination.
NY Times
JANUARY 14, 2022
Financial planning for people with chronic diseases is complicated and multifaceted. Start by building a team of people to help.
Drug Patent Watch
JANUARY 14, 2022
Annual Drug Patent Expirations for GOCOVRI Gocovri is a drug marketed by Adamas Pharma and is included in one NDA. It is available from one supplier. There are seventeen patents…. The post New patent for Adamas Pharma drug GOCOVRI appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
145 
Let's personalize your content